BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19888861)

  • 21. Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma.
    Salajegheh A; Pakneshan S; Rahman A; Dolan-Evans E; Zhang S; Kwong E; Gopalan V; Lo CY; Smith RA; Lam AK
    Hum Pathol; 2013 Oct; 44(10):2204-12. PubMed ID: 23845470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of vascular endothelial growth factor and epidermal growth factor in development of papillary thyroid cancer.
    Konturek A; Barczyński M; Cichoń S; Pituch-Noworolska A; Jonkisz J; Cichoń W
    Langenbecks Arch Surg; 2005 Jun; 390(3):216-21. PubMed ID: 15690202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma.
    Karaca Z; Tanriverdi F; Unluhizarci K; Ozturk F; Gokahmetoglu S; Elbuken G; Cakir I; Bayram F; Kelestimur F
    Eur J Endocrinol; 2011 Feb; 164(2):277-84. PubMed ID: 21097568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation.
    Tuttle RM; Fleisher M; Francis GL; Robbins RJ
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1737-42. PubMed ID: 11932308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered chemokine receptor expression in papillary thyroid cancer.
    González HE; Leiva A; Tobar H; Böhmwald K; Tapia G; Torres J; Mosso LM; Bueno SM; Gonzalez P; Kalergis AM; Riedel CA
    Thyroid; 2009 Sep; 19(9):957-65. PubMed ID: 19731977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma.
    Yu XM; Lo CY; Lam AK; Leung P; Luk JM
    Ann Surg; 2008 Mar; 247(3):483-9. PubMed ID: 18376194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between preoperative serum TSH levels and expression of VEGF in papillary thyroid carcinoma.
    Li J; Teng L; Jiang H
    Asia Pac J Clin Oncol; 2014 Jun; 10(2):149-52. PubMed ID: 23718885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of vascular endothelial growth factor (VEGF) in human thyroid tumors.
    Lewy-Trenda I; Wierzchniewska-Ławska A
    Pol J Pathol; 2002; 53(3):129-32. PubMed ID: 12476614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical levels of cyclo-oxygenase-2, matrix metalloproteinase-9 and vascular endothelial growth factor in papillary thyroid carcinoma and their clinicopathological correlations.
    Meng XY; Zhang Q; Li Q; Lin S; Li J
    J Int Med Res; 2014 Jun; 42(3):619-27. PubMed ID: 24670538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of decoy receptor 3 in diffuse sclerosing variant of papillary thyroid carcinoma: correlation with M2 macrophage differentiation and lymphatic invasion.
    Chang WC; Chen JY; Lee CH; Yang AH
    Thyroid; 2013 Jun; 23(6):720-6. PubMed ID: 23186064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway.
    Kim DS; Franklyn JA; Boelaert K; Eggo MC; Watkinson JC; McCabe CJ
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4603-11. PubMed ID: 16926250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.
    Chou CK; Yang KD; Chou FF; Huang CC; Lan YW; Lee YF; Kang HY; Liu RT
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E196-205. PubMed ID: 23264400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nitric oxide in papillary thyroid carcinoma: induction of vascular endothelial growth factor D and correlation with lymph node metastasis.
    Nakamura Y; Yasuoka H; Zuo H; Takamura Y; Miyauchi A; Nakamura M; Kakudo K
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1582-5. PubMed ID: 16418215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis.
    Ma H; Yan J; Zhang C; Qin S; Qin L; Liu L; Wang X; Li N
    Int J Clin Exp Pathol; 2014; 7(11):7999-8007. PubMed ID: 25550843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
    Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
    Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical significance of HIF-1 alpha,VEGF and VEGF-C expression in papillary thyroid carcinoma].
    Wang Y; Hua Q
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Mar; 21(5):204-6, 208. PubMed ID: 17536453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.
    Ngan ES; Lang BH; Liu T; Shum CK; So MT; Lau DK; Leon TY; Cherny SS; Tsai SY; Lo CY; Khoo US; Tam PK; Garcia-Barceló MM
    J Natl Cancer Inst; 2009 Feb; 101(3):162-75. PubMed ID: 19176457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The expression of monocyte chemotactic protein-1 in papillary thyroid carcinoma is correlated with lymph node metastasis and tumor recurrence.
    Tanaka K; Kurebayashi J; Sohda M; Nomura T; Prabhakar U; Yan L; Sonoo H
    Thyroid; 2009 Jan; 19(1):21-5. PubMed ID: 19072670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas.
    Kilicarslan AB; Ogus M; Arici C; Pestereli HE; Cakir M; Karpuzoglu G
    APMIS; 2003 Mar; 111(3):439-43. PubMed ID: 12752224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different CXCR4 expression according to various histologic subtype of papillary thyroid carcinoma.
    Shin DY; Kim KJ; Ku CR; Lee MK; Jee SI; Chung WY; Lee EJ
    Endocr Pathol; 2013 Dec; 24(4):169-76. PubMed ID: 23963832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.